**Treatment ofAcinetobacterInfections**

Fishbain, Joel
Peleg, Anton Y.

¹ Division of Infectious Diseases, St John Hospital and Medical Center, Detroit, Michigan
² Division of Infectious Diseases, Massachusetts General Hospital and Beth Israel Deaconess Medical Center, Boston, Massachusetts
³ Alfred Hospital, Monash University, Melbourne, Australia
⁴ Department of Microbiology, Monash University, Melbourne, Australia

Received 13 January 2010; accepted 9 March 2010; electronically published 26 May 2010.

Reprints or correspondence: Dr Joel Fishbain, Div of Infectious Diseases, St John Hospital and Medical Ctr, 19251 Mack Ave, Ste 333, Grosse Pointe Woods, Michigan 48236 ([email protected]).

1058-4838/2010/5101-0013$15.00

Clinical Infectious Diseases 51(1):p 79-84, July 1, 2010. | DOI: 10.1086/653120

Acinetobacter baumannii remains an important and difficult-to-treat pathogen whose resistance patterns result in significant challenges for the clinician. Despite the prevalence and interest in A. baumannii infections, there is relatively limited wellcontrolled scientific data to help the clinician select optimal empirical and subsequent targeted therapy for a variety of infections. We will review the currently available antimicrobial agents and discuss the clinical data supporting the use of the various agents.